These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24484760)

  • 21. Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH.
    Brookman-Amissah N; Duchesnes C; Williamson MP; Wang Q; Ahmed A; Feneley MR; Mackay A; Freeman A; Fenwick K; Iravani M; Weber B; Ashworth A; Masters JR
    Prostate Cancer Prostatic Dis; 2005; 8(4):335-43. PubMed ID: 16130014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Words of wisdom: re: prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.
    Maitland NJ
    Eur Urol; 2013 Aug; 64(2):341-2. PubMed ID: 23830230
    [No Abstract]   [Full Text] [Related]  

  • 23. Discovery of genomic alterations through coregulation analysis of closely linked genes: a frequent gain in 17q25.3 in prostate cancer.
    Bermudo R; Abia D; Benitez D; Carrió A; Vilella R; Ortiz AR; Thomson TM; Fernández PL
    Ann N Y Acad Sci; 2010 Oct; 1210():17-24. PubMed ID: 20973795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct genomic aberrations associated with ERG rearranged prostate cancer.
    Demichelis F; Setlur SR; Beroukhim R; Perner S; Korbel JO; Lafargue CJ; Pflueger D; Pina C; Hofer MD; Sboner A; Svensson MA; Rickman DS; Urban A; Snyder M; Meyerson M; Lee C; Gerstein MB; Kuefer R; Rubin MA
    Genes Chromosomes Cancer; 2009 Apr; 48(4):366-80. PubMed ID: 19156837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytogenomic aberrations associated with prostate cancer.
    Gu G; Brothman AR
    Cancer Genet; 2011 Feb; 204(2):57-67. PubMed ID: 21504704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide gene expression analysis of prostate carcinoma.
    Gerald WL
    Semin Oncol; 2003 Oct; 30(5):635-48. PubMed ID: 14571411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors.
    Hawley JR; Zhou S; Arlidge C; Grillo G; Kron KJ; Hugh-White R; van der Kwast TH; Fraser M; Boutros PC; Bristow RG; Lupien M
    Cancer Res; 2021 Dec; 81(23):5833-5848. PubMed ID: 34642184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer: Tumour genomes are highly plastic.
    Stone L
    Nat Rev Urol; 2016 Aug; 13(8):438. PubMed ID: 27400668
    [No Abstract]   [Full Text] [Related]  

  • 29. Clusterin is epigenetically regulated in prostate cancer.
    Rauhala HE; Porkka KP; Saramäki OR; Tammela TL; Visakorpi T
    Int J Cancer; 2008 Oct; 123(7):1601-9. PubMed ID: 18649357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic basis and clonal evolution of human prostate cancer.
    Kallioniemi OP; Visakorpi T
    Adv Cancer Res; 1996; 68():225-55. PubMed ID: 8712069
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of miR-452-5p in the tumorigenesis of prostate cancer: A study based on the Cancer Genome Atl(TCGA), Gene Expression Omnibus (GEO), and bioinformatics analysis.
    Gao L; Zhang LJ; Li SH; Wei LL; Luo B; He RQ; Xia S
    Pathol Res Pract; 2018 May; 214(5):732-749. PubMed ID: 29559248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer.
    Bermudo R; Abia D; Ferrer B; Nayach I; Benguria A; Zaballos A; del Rey J; Miró R; Campo E; Martínez-A C; Ortiz AR; Fernández PL; Thomson TM
    BMC Cancer; 2008 Oct; 8():315. PubMed ID: 18973659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chromosome changes in prostatic cancer. Historic evolution and future perspective].
    Alcaraz A; Carretero P
    Actas Urol Esp; 1995; 19(7):539-43. PubMed ID: 8815664
    [No Abstract]   [Full Text] [Related]  

  • 34. Words of wisdom: Re: TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c.
    Culig Z
    Eur Urol; 2014 May; 65(5):1011. PubMed ID: 24646496
    [No Abstract]   [Full Text] [Related]  

  • 35. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.
    Liu W
    Asian J Androl; 2016; 18(4):533-42. PubMed ID: 26975494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolutionary conservation of zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer.
    Eisermann K; Tandon S; Bazarov A; Brett A; Fraizer G; Piontkivska H
    BMC Genomics; 2008 Jul; 9():337. PubMed ID: 18631392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Necessity and usefulness of bioinformatic methods for microarray data analysis].
    Kestler HA; Küfer R
    Urologe A; 2004 Jun; 43(6):669-74. PubMed ID: 15112041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Words of wisdom: re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Luo J; Pienta KJ
    Eur Urol; 2013 Aug; 64(2):339-40. PubMed ID: 23830228
    [No Abstract]   [Full Text] [Related]  

  • 39. Words of wisdom. Re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Schrader AJ; Schrader MG; Cronauer MV
    Eur Urol; 2013 Jul; 64(1):169-70. PubMed ID: 23746320
    [No Abstract]   [Full Text] [Related]  

  • 40. [Recent advancements in prostate cancer basic research].
    Inoue T; Ogawa O
    Nihon Rinsho; 2016 Jan; 74(1):7-12. PubMed ID: 26793872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.